Valuation under review.
Veraxa Biotech is a Swiss-based clinical-stage biotechnology company developing proprietary drug discovery and antibody engineering platforms, including droplet-based microfluidic screening for high-throughput antibody discovery, genetic code expansion for precise protein modification, and tetrazin-based click chemistry for antibody-drug conjugate synthesis. The company is advancing a pipeline of therapeutic candidates focused on oncology, particularly rare hematopoietic malignancies and solid tumors amenable to dual-antigen targeting approaches, such as its anti-FLT3 monoclonal antibody currently in clinical development. As an R&D-stage enterprise with no commercial product revenue, Veraxa generates no sales and instead funds its operations through capital raises while advancing its technology platforms and drug candidates through preclinical and clinical development stages.
Financial summary not available yet.